Granules India Receives USFDA EIR for Bonthapally Facility
Granules India Limited, a pharmaceutical manufacturing company, has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its API Unit-I facility located at Bonthapally, Hyderabad.
The company's achievement is a significant milestone in the pharmaceutical industry.
No statement from the company or FDA is available.
For more information, contact can be made at [email protected] or 011-43720751.
Authors: Ruchika Sharma and Dr. Kamal Kant Kohli.
Author summary: Granules India gets USFDA approval.
More News
- Swansea City v Manchester City | How to watch or listen | Swansea
- Trackhouse's incredible rise reflects MotoGP's shifting landscape
- GRID Powers Up: XSite Braehead Unveils Bold New Identity
- Menezes to Return to LMP2 with High Class – Sportscar365
- Andy Cohen Praises a Dallas Church for its Reponse to Gov. Abbott's War on Crosswalks
- Gmail Data Breach: 183 million accounts exposed in massive leak
- When Bill Skarsgård's Pennywise Appears in It TV Show Possibly Revealed - Comic Book Movies and Superhero Movie News - SuperHeroHype
- Elaine Hendrix on Vegan Living, ‘Dancing With the Stars’, and Life After ‘The Parent Trap’
- Glaude urges a simple reponse to MAGA: 'You're lying' – Baptist News Global
- News from Finali Mondiali paddock